Published 4 issues per year
ISSN Print: 0893-9675
ISSN Online: 2162-6448
Indexed in
The Roles of Chromatin Remodeling Genes in Pancreatic-Biliary Malignancies
ABSTRACT
Recent studies have definitively established that chromatin remodeling is a crucial epigenetic mechanism not only in physiological conditions but also in influencing cancer biology. It is a dynamic process in which the chromatin, the functional entity of DNA, can undergo specific modifications by obtaining transcriptional activation or transcriptional silencing. One of the most important recent discoveries in cancer genetics and genomics is that the genes involved in the establishment of chromatin structure, the so called chromatin remodelers, are frequently mutated in different types of human cancer. This review aims to summarize the main novelties related to this topic, describing also the contribution of such genes during oncogenesis. Particularly, we focus on the switch/sucrose non-fermentable complexes and on three of the most important chromatin remodeling genes in biliary and pancreatic cancer: ARID1A, PBRM1, and BAP1.
-
Riva Giulio, Pea Antonio, Pilati Camilla, Fiadone Giulia, Lawlor Rita Teresa, Scarpa Aldo, Luchini Claudio, Histo-molecular oncogenesis of pancreatic cancer: From precancerous lesions to invasive ductal adenocarcinoma, World Journal of Gastrointestinal Oncology, 10, 10, 2018. Crossref
-
Pea Antonio, Cheng Liang, Luchini Claudio, Dissecting the molecular landscape of pancreatic cancer: towards a precision medicine approach, Expert Review of Precision Medicine and Drug Development, 4, 3, 2019. Crossref
-
Yang Wen-Wei, Yang Lin, Lu Hai-Zhen, Sun Yong-Kun, Long-term survival of a patient with pancreatic cancer and lung metastasis: A case report and review of literature, World Journal of Clinical Cases, 9, 30, 2021. Crossref
-
Bourien Héloïse, Lamarca Angela, McNamara Mairéad G, Hubner Richard A, Valle Juan W, Edeline Julien, Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials, Expert Opinion on Investigational Drugs, 30, 9, 2021. Crossref